Multiple Myeloma

Centering discussion on RedirecTT-1, expert hematologist-oncologists consider safety and efficacy data with the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.

Shared perspective on available novel therapies in relapsed/refractory multiple myeloma and how best to sequence these agents.

Panelists reflect on the evolving landscape of BCMA targeting bispecifics and how additional agents will impact the management of multiple myeloma.

Key opinion leaders consider when it is appropriate to utilize bispecific dose holds or reductions when treating patients with multiple myeloma.

The panel highlights remaining unmet needs in the management of multiple myeloma and speculates on the future of treatment.

Noffar Bar, MD, shares how she would choose between the potential bispecific antibodies for treatment of multiple myeloma after recent data updates.

Nausheen Ahmed, MD, and Al-Ola Abdallah, MD, discuss the use of CAR T-cell therapy in patients with transplant-ineligible multiple myeloma.

The expert panel gives an overview of factors that influence treatment decisions in patients with transplant-ineligible multiple myeloma.

Focused discussion on the advent of cytokine release syndrome in MajesTEC-1 and how it compared to the benefits derived from teclistamab therapy.

Experts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.

Expert hematologist-oncologists identify long-term data from MonumenTAL-1 regarding infection rates in patients with relapsed/refractory multiple myeloma.

Following their review of data from MonumenTAL-1, Ajai Chari, MD, and Carolina Schinke, MD, share practical considerations for real-world use of talquetamab in relapsed/refractory multiple myeloma.

Focused discussion on how patients receiving bispecific therapy for multiple myeloma are transitioned into and managed within the community setting.

Expert panelists share insight on transitioning patients on bispecific therapy from an academic or specialty center to the community setting.

Catherine Wei, MD, and David Witt, MD, explain some of the reasons they would recommend treatment with bispecific antibodies to their patients with multiple myeloma.

Syed S. Ali, MD, and Noffar Bar, MD, share their practical experience with bispecific antibodies in the treatment of patients with multiple myeloma.

Experts on multiple myeloma discuss how to select treatment options in later lines of therapy.

Leyla O. Shune, MD, reviews the MAIA trial, which looked at DRd vs Rd in patients with transplant-ineligible multiple myeloma.

The expert panel presents the case of a patient with multiple myeloma and discusses evaluating transplant eligibility in patients with MM.

Before closing out their module on relapsed/refractory multiple myeloma, key opinion leaders reflect on the role of CAR T-cell therapy and patient access to care.

A panel of experts discuss unmet needs in multiple myeloma and offer perspectives on the future treatment landscape.

Centering discussion on bispecific therapy, panelists consider dosing strategies and adverse event management in relapsed/refractory multiple myeloma.

An expert panel compares bispecific antibodies with CAR T-cell therapy and discusses treatment sequencing.

Focused discussion on the safety and efficacy data from MonumenTAL-1, which utilized talquetamab monotherapy in patients with relapsed/refractory multiple myeloma.

Following a brief review of the relapsed/refractory multiple myeloma treatment landscape, Carolina Schinke, MD, provides an overview of the MonumenTAL-1 study design.